GU CONNECT has summarised the prostate cancer highlights from ESMO 2016 - Copenhagen for you.
Prostate cancer update by Asst. Prof. Tanya Dorff
GU CONNECT has summarised the prostate cancer highlights from ESMO 2016 - Copenhagen for you.
Prostate cancer update by Asst. Prof. Tanya Dorff
Following a residency at Mt. Sinai Hospital in New York City, Dr Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr Dorff serves as an associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology. She has lectured on prostate and bladder cancer treatment nationally and internationally and has presented her research at national meetings. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and immunotherapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.
AstraZeneca, Astellas, Exelixis, Janssen and SeaGen.
Recommendations for best practice
Paper published in Journal of Gastrointestinal Cancer
Maximising outcomes for patients with advanced neuroendocrine tumours
Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer
Maximising outcomes for patients with advanced RCC
Medical experts make recommendations for best practice